Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications

Abstract

The cost of immunoprophylaxis with palivizumab far exceeded the economic benefit of preventing hospitalizations, even in infants at highest risk for RSV infection.